Founded by Dr. Alison Armour, who led the clinical development of Pluvicto®, the world's leading radiopharmaceutical drug, Curadh is headed by an expert team in MTR development. Curadh Inquiries ...

FDA approved to help select patients with metastatic prostate cancer for radioligand therapy before chemotherapy.

Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier disease stage ...

Telix Pharmaceuticals Limited (NASDAQ: TLX) is one of the 7 Best ASX Stocks to Buy Now. On June 23, the company announced ...

Pluvicto is an intravenous RLT that combines a targeting compound (a ligand) with a therapeutic radionuclide (a radioactive particle, in this case lutetium-177) 5,7. After administration into the ...

Pluvicto is part of a class of drugs that combines cell-killing radioactive particles with molecules that attach themselves to tumours, where Novartis has a leading position. The drug saw first ...

Northwell’s Phelps Hospital is the first and only medical facility in New York State between the Bronx and Albany to offer Pluvicto, a groundbreaking treatment for men with advanced prostate […] ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...